Defibrillators and cardiac resynchronization therapy as a bridge to cardiac transplantation

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Heart failure remains a significant health burden despite medical treatments, characterized by progression, hospitalizations, and mortality.
• Ventricular tachyarrhythmias and pump failure contribute to mortality in heart failure patients.
• Device therapy has emerged as a critical intervention for selected heart failure populations.

Purpose of the Study:

• To highlight the established role of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) in managing chronic heart failure.
• To emphasize the benefits of CRT and ICDs in improving outcomes for patients with drug-refractory heart failure.

Main Methods:

• Review of established clinical guidelines and evidence supporting device therapy in heart failure.
• Analysis of the impact of CRT and ICDs on morbidity and survival rates.
• Evaluation of the potential of these devices to prevent end-stage heart failure.

Main Results:

• ICDs and CRT are standard of care for selected patients with chronic heart failure.
• These devices reduce morbidity and increase survival in patients with drug-refractory heart failure.
• Device therapy can delay or prevent the need for cardiac transplantation.

Conclusions:

• Implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) are essential components of modern heart failure management.
• Device therapy offers significant benefits in reducing mortality and improving quality of life for eligible heart failure patients.
• Continued research and application of device therapy are crucial for advancing heart failure care.